B cells in SLE: Different biological drugs for different pathogenic mechanisms

被引:18
作者
Diamanti, Andrea Picchianti [1 ]
Rosado, M. Manuela [2 ]
Carsetti, Rita [2 ]
Valesini, Guido [1 ]
机构
[1] Univ Roma La Sapienza, Dipartimento Clin & Terapia Med, Policlin Umberto I, Rome, Italy
[2] IRCCS, Osped Pediat Bambino Gesu, Res Ctr, I-00165 Rome, Italy
关键词
SLE; B cells; autoantibodies; biologic drugs;
D O I
10.1016/j.autrev.2007.02.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a complex multi-factorial pathogenesis and a great clinical polymorphism. SLE is considered to be a B cell disease in which autoantibodies are the major players. Recently, the central role of B cells has been confirmed and it has been shown that that the relative frequency of B cells subsets is altered in SLE patients. Conventional immunosuppressive therapies such as azathioprine, cyclophosphamide or methotrexate, reduce disease activity and improves the patient's general health conditions. These treatments have possible side effects; in fact they could compromise liver function, fertility and innate and adaptive immune responses. Moreover, for unknown reasons a small group of SLE patients is refractory to immunosuppressive therapy In these cases finding an effective treatment becomes a challenge. The progress in therapeutic antibody technology has led to the production of a wide array of humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune disorders. In contrast to general immuno-suppression, the availability of drugs interfering with specific pathogenetic pathways gives the possibility to choose therapies tailored to each disease in each patient. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 40 条
[1]   Die and let live: Eliminating dangerous lymphocytes [J].
Abbas, AK .
CELL, 1996, 84 (05) :655-657
[2]   LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study [J].
Alarcón-Segovia, D ;
Tumlin, JA ;
Furie, RA ;
McKay, JD ;
Cardiel, MH ;
Strand, V ;
Bagin, RG ;
Linnik, MD ;
Hepburn, B .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :442-454
[3]   B cells in human and murine systemic lupus erythematosus [J].
Anolik, J ;
Sanz, I .
CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (05) :505-512
[4]   BLyS - an essential survival factor for B cells: basic biology, links to pathology and therapeutic target [J].
Baker, KP .
AUTOIMMUNITY REVIEWS, 2004, 3 (05) :368-375
[5]   Autoimmunity through cytokine-induced dendritic cell activation [J].
Banchereau, J ;
Pascual, V ;
Palucka, AK .
IMMUNITY, 2004, 20 (05) :539-550
[6]   BAFF mediates survival of peripheral immature B lymphocytes [J].
Batten, M ;
Groom, J ;
Cachero, TG ;
Qian, F ;
Schneider, P ;
Tschopp, J ;
Browning, JL ;
Mackay, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (10) :1453-1465
[7]   The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS) [J].
Beebe, AM ;
Cua, DJ ;
Malefyt, RD .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (4-5) :403-412
[8]   A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J].
Boumpas, DT ;
Furie, R ;
Manzi, S ;
Illei, GG ;
Wallace, DJ ;
Balow, JE ;
Vaishnaw, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :719-727
[9]   B cells move to centre stage: novel opportunities for autoimmune disease treatment [J].
Browning, Jeffrey L. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (07) :564-576
[10]   The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity [J].
Cancro, M. P. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 :34-36